1. Operating as:
April 2011

2. Disclaimer
Neither this presentation nor any of its contents are to be distributed to third parties without the prior written consent of China Health Labs & Diagnostics Ltd.
(“China Health Labs”). This presentation supersedes and replaces any and all material s which may have been provided to potential investors. There are certain
risks inherent in an investment in the securities of China Health Labs, which prospective investors should carefully consider before investing in the securities of
China Health Labs. Reference is made to the section entitled “Risk Factors” in the draft Filing Statement of China Health Labs dated May 30, 2010, which section
is incorporated by reference into this investor presentation, for a discussion of the risks inherent in an investment in the securities of China Health Labs. The draft
Filing Statement is available on SEDAR at www.sedar.com under China Health Labs’s profile.
This presentation is not, and under no circumstances is it to be construed as, an advertisement or a public offering of these securities. This presentation is
personal to each offeree and does not constitute an offer to any other person or to the public generally to subscribe for or otherwise acquire any of the securities
referred to herein. No securities regulatory authority or similar authority has reviewed or in any way passed upon the presentation or the merits of these securities
and any representation to the contrary is an offence. This presentation has been prepared for information purposes only in order to assist prospective investors in
evaluating an investment in China Health Labs.
Except for the statements of historical fact, the information contained herein may be of a forward-looking nature. Such forward-looking information involves
known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement of China Health Labs to be materially
different from any future results, performance or achievements expressed or implied by statements containing forward-looking information. Although China Health
Labs has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as
anticipated, estimated or intended. There can be no assurance that statements containing forward looking information will prove to be accurate as actual results
and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on statements
containing forward looking information.
The information contained herein includes market and industry data that has been obtained from third party sources, including industry publications, as well as
industry data prepared by China Health Labs management on the basis of its knowledge of and experience in the industry in which China Health Labs operates.
Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to
the accuracy or completeness of included data. China Health Labs believes that its industry data is accurate and that its estimates and assumptions are reasonable,
but there is no assurance as to the accuracy or completeness of this included data. Although the data is believed to be reliable, China Health Labs has not
independently verified any of the information from third party sources referred to in this presentation or ascertained the underlying economic assumptions relied
upon by such sources.
2

3. Mission Statement
To be the leading provider of total lab solutions for
medical diagnostics and food safety in China
3

4. Company Overview
Who We Are
China Health Labs & Diagnostics is a leading provider of total lab solutions for medical
diagnostics and food safety in China
• We develop and sell proprietary total lab solutions to targeted sectors and sell diagnostic equipment & reagents to
large urban hospitals
• We generate revenues from the sale of solutions and equipment, and recurring revenues from reagents and service
• We manufacture our own propriety equipment and reagents in our Beijing facility
2010 Performance & Status
Revenue growth of 41% to 33.7 million
Net Income growth of 41% to $5.5 million equal to EPS of $0.10
Net income growth of 78% and EPS of $0.12 excluding one-time going public expense
Installed 124 rural labs to have total 210. Secured bid for 587 new locations in Jilin
More than doubled sales of POCT solutions to the Chinese military
Increased sales of food safety solution to Beijing municipal government by over 40%
Increased sales of equipment and reagents by 19% to large urban hospitals
4
4

5. Growth Strategy
• Only provider of total lab solutions to our targeted sectors, providing premium value
compared with individual products
Provide Solutions • Total lab solutions combines equipment, software, installation & training and ongoing
supply of reagents and service
• Building tremendous customer loyalty and multiple recurring revenue streams
• On solutions where we have competitive advantages in technology and relationships
Focus Resources • On sectors that have Chinese government policy and budget support
• On sectors where we have limited competition and large market potential
• Total rural hospital lab solution
Leverage Track Record • POCT solutions for military and emergency rescue applications
to Build Market Share • Food safety testing solutions
• Selected products for large urban hospitals
Collaborative Product • Developed rural lab solution with provincial and central government Ministry of Health
& Service • Joint R&D agreement with the Chinese military
Development • Developed food safety testing solution with the Beijing government
• Reagent technology that can enhance ongoing revenues to rural labs and urban hospitals
Acquisitions and • Small size medical equipment and manufacturers with established brands, high quality
partnerships products and complementary customers
5

6. China Market Size and Growth
• Large and growing market, driven by increasing Chinese wealth and growing
consumer demand for improved health care
• Trend towards universal health care system
• Chinese government policy and budget support for our key sectors: improved rural
health care, emergency and rescue services and food safety
China’s Medical Device Market China’s Per Capita Healthcare Expenditures (2006)
US$ Billions
Sources: China: Accessing the Medical Device Market. Espicom Business Intelligence, July 2007; Report of Chinese Medical Instrument Industry under International Financial Crisis, 2009;
The Red Hot Market for Medical Devices in China by: Evelyn Rubin September 08, 2006; How will China's healthcare reform affect the medical device sector in 2009? by Glenn Hou
6

7. Business Sectors
• Started business in 1993 by
importing equipment and
reagents for large urban hospitals
• 2010 growth driven by 100%
increase in sales of total lab
solutions to three new sectors
• In 2010 three new sectors
increased to 41% of revenues
from less than 30% in 2009, trend
to continue in 2011 and beyond
• Generate higher margins in new
sectors due to proprietary
solutions and limited competition
7

8. Products and Services
1) Rural hospital lab solution
5) Equipment & Reagents
2) Point-of-Care
Technology
Solution
4) Service, training and
support services 3) Food safety ‘quick-
test’ lab solution
Strong suite of complementary products
8

9. Large Urban Hospitals
Overview
• Large existing market served by many Chinese and international players
• Lower margins than for total lab solutions business
Competitive Advantages Photo
• Long term market presence, since 1993
• Strong market position with deliveries to
more than 500 of the 1000 biggest hospitals
• Competitive product range with a
combination of imported and locally made
products
• In 2010, revenues grew by 19% and accounted
for 59% of total revenues
• Opportunity to accelerate growth if we
localize production of high quality reagents
9

10. Rural Hospitals and Labs
Overview
• Turnkey package of diagnostic testing equipment, installation & training, hardware and software and
ongoing reagent supply & service
• Company estimates market opportunity is approximately $2 billion over next 5 years based on
50,000 existing and 40,000 new rural hospitals throughout China
Competitive Advantages Photo
• First-mover advantage to aggressively roll out
network of clinics before competition can
establish a comparable product
• Installed base of 210 rural hospitals plus new
bid to install 587 – at least 797 for 2011
• Initial revenues and profits from installation and
recurring revenues from reagents and service
• Currently no competitors due to high barriers to
entry: long certification process, requirement
for full suite of complementary products,
relationships with provincial governments
10

11. Military & Emergency Rescue Services
Overview
• Point of Care Technology (“POCT”) Dry-chemistry diagnostic solution for use in ‘out-of-lab’
environments where urgent diagnosis is required (natural catastrophes, military settings)
– Used in joint military exercises and disaster relief in China, Haiti, Pakistan, Peru and Indonesia
Competitive Advantages Photos
• China Health is the only supplier in China
• Closed system with exclusive reagent supply
• Patented system protected by registered
copyright
• Chinese military bought 17 systems in 2009 &
more than doubled order in 2010
• Developing full range of POCT products with
Chinese military in three year R&D
agreement
• 13 systems sold to NERT in 2011
• Appeals to international markets
11

12. Food Safety Testing
Overview
• Lab solutions for the PRC government to test the safety of food for public consumption
– Tests the chemical or biochemical index of food items similar to testing that of the human body
Competitive Advantages Photo
• Established market
– established business in 2008 for Beijing
Olympics, later set up 17 large food safety
testing labs for the Beijing government at food
distribution centers, mini-labs and mobile labs
– Beijing government increased order in 2010
• New LIS and mobile POCT products under
development
• Use “Beijing Model” as reference site to sell
solution to additional cities in China
• Company estimates that total Chinese
market opportunity is over $1 billion for 50
largest cities in China (660 cities in China)
12

13. Locations and Distribution
Facilities
• Beijing: HQ and 15,600 m2 production facility
Company facility Heilongjiang
• Guangdong: Sales and distribution hub Direct sales force presence
Planned sales force expansion Jilin
• Shanghai: Sales office
Liaoning
Direct Sales and distribution Beijing
• 58 person sales force, with direct sales in 12 Hebei
regions Shanxi Tianjin
• Direct sales of of total lab solutions Henan
• Third party wholesale distribution network, Shanghai
consisting of approximately 25 distributors for Jiangsu
large urban hospitals Sichuan
Jiangxi Zhejiang
Import business
• Typically highly advanced equipment
Guangdong
• Exclusive distributor in China for 3 European Guangxi
medical device manufacturers
• Partners include Trinity Biotech, Toshiba, Boule
Medical AB, Eschweiler, Maxmat, Abbott
Laboratories, and Elektronika 77
In-place manufacturing operating at 25% capacity to support internal growth
13

14. Management and Board
Management
• Founded Biochem Group in 1993
Shiping (Wilson) Yao
• 20 years experience in the medical equipment industry
President, CEO, Chairman and
• Member of China’s National Standardization Technical Committee
Director
• Member of the Board of Renmin University of China
Yuqiang Tang
• Over 15 years of managerial, sales and marketing experience
COO, Director
Bill Tunbrant • Wide range of experience in the medical equipment industry, as well as in international manufacturing
VP of Marketing, Director • Former director of Nibe Industrier AB (OMX: NIBE’B)
Adam Kniec • Founder of ArkOrion Enterprises Inc., a provider of accounting and financial reporting services to Canadian
CFO and US publicly traded companies
Chao Zhang
• 10 years financial management experience in the medical equipment and private health care industries
VP of Finance
Stephen D. Wortley
• Currently a partner at the law firm Lang Michener LLP
Secretary
Non-Executive (independent) Directors
• Deputy Dean of the School of Finance of Renmin University
Yumin Zhuang
• Independent supervisor with China CITIC Bank
Hong Chang • Physician with the University Health Network in Toronto
• Director of Migao Corporation (TSX: MGO)
Paul Haber
• Former Vice President, Chief Financial Officer and Corporate Secretary of QuStream Corporation (TSXV:QVC)
• Director of Zongshen PEM Power Systems (TSX: ZPP)
Kim Oishi • Former President and Director of Hanfeng Evergreen (TSX: HF); Senior Vice President of Hanwei Energy (TSX:
HE); Director of Cantronic Systems (TSX-V: CTS); and Grand Power Logistics (TSX-V: GPW)
14

15. Financial Highlights
000’s (except per share amounts)
2010 2009 Change
Revenue $33,705 $23,824 41%
Gross Margin 39.3% 34.7% 13%
Net Income $5,527 $3,914 41%
EPS - Diluted $0.10 $0.07 43%
WANS - Diluted 55,188 52,233 6%
Total Assets $37,081 $21,361 74%
Long Term Financial $Nil $Nil
Liabilities
• Strong revenue growth and margins drive earnings growth
• Net income growth of 78% and EPS of $0.12 in 2010, if one time QT expenses are excluded
• Sufficient funding to continue growth in 2011
• May need additional debt of equity to for acquisition or for large rural lab contract
15

16. Outlook
• Expect continued strong revenue growth in 2011 and beyond, driven by growth
of total lab solutions for three key sectors
• Expect growth of revenue from large urban hospitals to be lower, such that total
lab solutions to account for growing percentage of revenues
• Gross margins expected to be stable in 2011, supported by strong margins
from proprietary products and services
• Sufficient working capital and capacity to support 2011 growth
• Continued strong growth in net income and EPS expected for 2011
16

17. Appendix
17

18. History of the Company
1993 • Company founded by Mr. Wilson Yao in Guangzhou
• Began by providing distribution and services for medical diagnostic equipment to hospitals
1995 • Begin geographic expansion within China
1998 • Established offices outside of Guangdong, forming the basis for a regional distributors and service network
2003 • Transformed from distributor to manufacturer
• Relocated head office to Beijing
2007 • Began construction of a new R&D and production facility
• Awarded PRC state level and military tenders for laboratory equipment
• Developed Biochem branded lab information hardware and software system
• Launched the total lab solution in rural areas of China (20 rural labs in Henan province)
2008 • Recognized as being compliant with the PRC’s “Good Manufacturing Practice” (GMP)
• Entered into agreement Liaoning province to implement 66 rural labs
• PRC government began using Biochem Group products in food safety testing
2009 • R&D and production centre was officially placed into operation
• First batch of point-of-care-technology products were used in military exercises
2010 • Accumulated 60 PRC government issued production licenses for medical diagnostic equipment and reagents
• Focus on growth opportunities in rural diagnostic facilities, point-of-care-technology, and food testing
18
18

19. State of the Chinese Healthcare Industry
• Old system (pre 2009): Market-oriented (hospitals run as profit centers)
– Resulted in higher medical fees, making medical services less affordable to ordinary citizens
– Large development gap between urban and rural areas
– Low government funding
– Weak rural healthcare facilities
– Increasing disease burdens
• New system (post 2009): Universal health care
– Investment of RMB 850 billion (US$125 billion) over the next three years
– Focus on improving rural hospitals, public emergency rescue forces and good safety controls
– Expanding coverage of basic medical insurance from 30% today to 90% in 2011
China’s Health Care Expenditure as a % of GDP vs. G8 Nations (2006) China’s Hospital Beds per 10,000 Citizens vs. G8 Nations (2004-2006)
Source: OECD
19

20. Recent Sweeping Healthcare Reforms
• In April 2009, the Chinese government announced plans to reform China’s healthcare
system into a universal healthcare system
• The plan involves the following commitments:
– An investment of RMB 850 billion towards healthcare reform over the next three years;
– Prioritized development of small, rural hospitals and clinics
– Implement a diversified medical insurance system targeting coverage of over 90% of the
population by 2011
• The government has committed to undertake the following improvements:
– Upgrade basic treatment and diagnostic equipment at 50,000 existing township clinics
– Build 39,400 new diagnostic facilities, health clinics, hospitals and service centers primarily in
rural areas
– Train 1.37 million village doctors and 160,000 community doctors
Massive government reforms targeted at improving healthcare for rural citizens
Source: JP Morgan’s Hands-on China Report – March 9, 2009
20